Document is current
Any future updates will be listed below
-
Authors
Splinter, Marije J.
Henderson, Emily J.
Ben-Shlomo, Yoav
Darweesh, Sirwan K. L.
Sowa, Pawel
Wolters, Frank J.
Velek, Premysl
Meijerink, Hannie J. E. M.
Bakx, Paulus
Ikram, M. Arfan
de Schepper, Evelien I. T.
Ikram, M. Kamran
Licher, Silvan
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 22 November 2024
First Online: 5 December 2024
Declarations
:
: The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare, and Sport (Population Screening Act WBO, license number 1071272–159521-PG). PRIME-XS was approved by the London—Brighton & Sussex Research Ethics Committee (REC reference 20/LO/0890). PRIME-NL has been reviewed by the ethics committee of the Radboud University Nijmegen Medical Centre on the basis of the Dutch Code of conduct for health research, the Dutch Code of conduct for responsible use, the Dutch Personal Data Protection Act and the Medical Treatment Agreement Act. The ethics committee has passed a positive judgment on the study. The Bialystok PLUS Study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Bioethical Committee of Medical University of Bialystok, protocol code: APK.002.346.2020.
: Not applicable.
: The authors declare no competing interests.
